MayoComplete next-generation sequencing for hematologic and oncologic conditions
Every person affected by cancer needs unique care and treatment. Designed using Mayo Clinic’s extensive clinical experience and informed by the latest in cancer biomarker discovery and treatments, our suite of MayoComplete next-generation sequencing panels puts patients on the right path.
Mayo Clinic Laboratories’ robust suite of MayoComplete oncology and hematology testing uses next-generation sequencing to identify and evaluate the presence of mutations. Our testing approach includes:
Comprehensive panels with increased sensitivity and improved accuracy, designed to help you make informed decisions on your patients’ cancer care.
Complementary microarray, FISH, and IHC testing, enabling full-spectrum testing in one laboratory.
Personalized answers for patients
Ongoing, rapid advancements in cancer biomarker discovery and treatments, combined with the need for genetic testing to determine eligibility for certain therapies, require a dynamic testing approach that meets the needs of every patient. Each MayoComplete panel:
Provides diagnostic, prognostic, and therapeutic insights, including the latest targeted immunotherapies.
Is designed to ensure each patient receives the right test and personalized answers to guide their cancer journey.
Backed by Mayo Clinic expertise
Our MayoComplete suite of next-generation sequencing panels is developed, validated, and interpreted by Mayo Clinic geneticists, pathologists, oncologists, and hematologists to align with guidelines. Physicians who order our testing are also supported by:
24/7 access to our call center, always answered by a representative.
A team of board-certified geneticists and genetic counselors, who are available to assist with questions related to testing options and results interpretation.
Ongoing education, developed by Mayo Clinic experts, that covers the latest in hematology and oncology testing.
MayoComplete test menu
Learn more about our tailored next-generation sequencing panels for hematologic and oncologic conditions.
Acute myeloid leukemia
A comprehensive panel evaluates 47 genes to gain insights on hematologic neoplasms.
Focused acute myeloid leukemia subpanels give clinicians the flexibility to order the right tests for their patients.
Depending on the gene mutations in a tumor, certain therapies can be beneficial or harmful to a patient with colorectal cancer. Our panel identified 24% more patients who are unlikely to benefit from EGFR-targeted therapy.
Our panel covers the commonly mutated genes in gastrointestinal stromal tumors (GIST), assisting in diagnosis. This includes the most commonly mutated PDGFRA and KIT genes; NF1, BRAF, and other RAS genes; and SETD2 and TP53 mutations, which have been shown to take on an aggressive clinical course.
The simplified results of this test can be useful in determining diagnosis, assessing prognosis, and guiding treatment. It also provides MSI status.
This cell-free DNA test uses next-generation sequencing to evaluate peripheral blood for 33 genes.
This test is useful when answers are needed more quickly than a traditional biopsy process would allow; when tissue is not available for molecular testing; when tissue biopsy is not a viable option for the patient; and in patients with cancer in a location that is difficult to biopsy.
Our panel assesses for mutations in 12 genes and rearrangements in seven genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.
The results of this panel ensure that physicians have the information they need to target therapy for their patient. This genetic information can be useful in prognosis.
Our panel identifies variants in 17 genes associated with diagnosis, prognosis, and treatment guidance.
Offering increased sensitivity for heightened accuracy, our comprehensive melanoma evaluation includes full exonic sequencing of the genes, as opposed to evaluating only targeted areas. It can also help to identify difficult tumors or classify known tumors for targeted therapy guidance.
Our neuro-oncology panel is carefully curated to include only clinically relevant genes associated with brain tumors.
The panel evaluates mutations and rearrangements in 160 genes, including most abnormalities described by the World Health Organization 2021 classifications. This includes assessment of mutations in 89 genes and rearrangements in 81 genes, including 104 fusions and 29 transcript variants.
Our sarcoma fusion panel includes 169 genes and assesses mutations and fusions described in more than 50 types of soft tissue, bone, and other mesenchymal tumors.
Because fusion events can occur between known or novel gene partners, the panel is designed to provide the most comprehensive analysis by including 124 gene fusion pairs, 274 fusion variants, and novel gene partner detection.
